Sign up to save your podcasts
Or
Share Compass trials mark a milestone moment for the psychedelics sector
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Compass trials mark a milestone moment for the psychedelics sector
Compass Pathways CEO Kabir Nath believes psilocybin-based therapy could be transformational for patients with treatment-resistant depression—and his company is already preparing to deliver it at scale. Speaking at RBC Capital Markets’ Global Healthcare Conference, Nath shares his vision for Compass and the future of psilocybin therapy for treatment-resistant depression.
View all episodes
By RBC Capital Markets
5
1212 ratings
Compass Pathways CEO Kabir Nath believes psilocybin-based therapy could be transformational for patients with treatment-resistant depression—and his company is already preparing to deliver it at scale. Speaking at RBC Capital Markets’ Global Healthcare Conference, Nath shares his vision for Compass and the future of psilocybin therapy for treatment-resistant depression.
More shows like Pathfinders in Biopharma
View all
Motley Fool Money
3,229 Listeners
WSJ Your Money Briefing
1,727 Listeners
Exchanges
978 Listeners
Odd Lots
1,986 Listeners
WSJ Tech News Briefing
1,656 Listeners
The a16z Show
1,101 Listeners
The Long Run with Luke Timmerman
126 Listeners
The Readout Loud
338 Listeners
Wall Street Breakfast
1,043 Listeners
Thoughts on the Market
1,316 Listeners
The Journal.
6,125 Listeners
BioCentury This Week
34 Listeners
RBC's Markets in Motion
40 Listeners
Biotech Hangout
21 Listeners
Industries in Motion
10 Listeners
Powering Sustainable Ideas
0 Listeners
The Markets
86 Listeners
Strategic Alternatives
18 Listeners
The Top Line
15 Listeners
Macro Minutes
3 Listeners